Ongoing Clinical Trials for Non-Small Cell Lung Cancer Recurrent

There are currently 16 clinical trials studying new treatments for non-small cell lung cancer that has returned after treatment or is in advanced stages. These trials are testing various combinations of immunotherapy medications, targeted therapies, and chemotherapy across multiple European countries and beyond. The studies aim to improve survival rates, slow disease progression, and enhance quality of life for patients with this condition.

Clinical trial locations

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

This trial is comparing two different treatment approaches for advanced or recurrent lung cancer. Participants must be at least 18 years old with cancer that has spread to other parts of the body or has returned after treatment. The cancer must be visible on CT or MRI scans completed within 32 days before starting treatment, and participants should be generally healthy with a life expectancy of at least 3 months.

The main exclusion criteria include patients whose cancer type does not match the specific requirements or who fall outside the eligible age range. Vulnerable populations who cannot make decisions for themselves are also excluded from participation.

The study compares nivolumab and relatlimab combined with chemotherapy against pembrolizumab with chemotherapy. The goal is to determine which combination helps patients live longer by enhancing the immune system’s ability to fight cancer cells. Participants receive treatments through intravenous infusion, with close monitoring for side effects throughout the study period.

The investigational drugs include nivolumab, an immune checkpoint inhibitor that helps the immune system recognize cancer cells, relatlimab, which enhances immune response when used with nivolumab, and pembrolizumab, which also helps the immune system target cancer cells. These medications are given through intravenous infusion.

Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

This trial tests DS-3939a, a new treatment for advanced solid tumors that have spread beyond their original location. Participants must have adequate heart and organ function, measurable disease according to specific criteria, and an Eastern Cooperative Oncology Group performance status of 0 or 1, meaning they can carry out light work despite some symptoms.

Patients with metastatic or advanced solid tumors outside the specified age range or who belong to vulnerable populations cannot participate. Those who don’t meet safety and tolerability requirements for DS-3939a are also excluded.

The study is divided into two parts. The first part assesses safety and how well the body tolerates DS-3939a. The second part continues safety evaluations and measures treatment effectiveness through the objective response rate, which tracks how well the cancer responds to treatment.

DS-3939a is the primary investigational drug, designed to help treat advanced solid tumors. The study aims to understand if it’s safe and effective in shrinking or controlling tumor growth through intravenous infusion.

Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

This study treats patients with lung cancer that has spread or returned after previous treatment. Participants must be at least 18 years old with confirmed stage IV or recurrent cancer visible on CT or MRI scans. They must not have received previous systemic treatment for advanced cancer and should have good physical function with an ECOG Performance Status of 0 or 1.

Patients under 18, pregnant or breastfeeding women, those with active or untreated brain metastases, and people with active autoimmune disease cannot participate. Those who received other cancer treatments within 4 weeks before the study or have serious heart conditions are also excluded.

The treatment combines nivolumab given as an injection under the skin with ipilimumab administered through a vein, along with chemotherapy medications. The study monitors how the body processes these medications when given together and tracks participants’ responses and side effects throughout treatment.

The investigational drugs include nivolumab, which helps the immune system fight cancer cells through subcutaneous injection, ipilimumab, which activates the immune system through IV infusion, and various chemotherapy drugs to kill or stop cancer cell growth.

Study Comparing Ensartinib and Crizotinib for Patients with ALK-Positive Non-Small Cell Lung Cancer

This trial compares two oral treatments for lung cancer with a specific genetic change called ALK. Participants must have confirmed advanced or recurrent cancer with ALK positivity, measurable disease according to RECIST v. 1.1 guidelines, and the ability to swallow oral medication. They must be at least 18 years old with an ECOG Performance Status score between 0 and 2 and a life expectancy of at least 12 weeks.

Patients who received more than one prior chemotherapy treatment or were previously treated with an ALK tyrosine kinase inhibitor cannot participate. Those without ALK-positive cancer or outside the specified age range are also excluded.

The study randomly assigns participants to receive either ensartinib or crizotinib, both taken as oral capsules. Researchers monitor disease progression and side effects to determine which medication is more effective in controlling cancer and improving quality of life.

Ensartinib targets and blocks the ALK protein to help stop cancer cell growth. Crizotinib also targets the ALK protein, aiming to slow down or stop cancer cell growth. Both medications are compared to determine the most effective treatment option.

Study of INCB099280 and Adagrasib for Adults with Advanced Solid Tumors with KRASG12C Mutation

This study tests a combination of INCB099280 and adagrasib for advanced solid tumors with a specific genetic change called KRASG12C mutation. Participants must be at least 18 years old with an ECOG performance status of 0 or 1, a life expectancy of more than 3 months, and confirmed KRASG12C mutation in their cancer. They must have measurable disease and adequate organ function.

Patients outside the specified age range or belonging to vulnerable populations cannot participate. Those who don’t meet safety and tolerability requirements for the study drugs are also excluded.

The study evaluates the safety, tolerability, and effectiveness of combining INCB099280 and adagrasib. Both medications are taken as oral tablets. Researchers monitor participants for side effects and assess how well the treatment reduces tumor size.

INCB099280 is an investigational medication targeting specific cancer growth pathways. Adagrasib targets the KRASG12C mutation, blocking signals that tell cancer cells to grow and divide. The combination aims to determine their effectiveness together.

Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

This trial compares treatment combinations for advanced lung cancer that cannot be surgically removed or has spread. Participants must be at least 18 years old with cancer showing PD-L1 protein in at least 50% of cells. They must have measurable tumors, good organ function, and an ECOG Performance Status of 0 or 1. Both men and women must use reliable birth control during and after the study.

Patients with other cancer types, previous interfering treatments, serious heart conditions, or those pregnant or breastfeeding cannot participate. People unable to follow study procedures or attend required visits are also excluded.

Participants are randomly assigned to receive either ociperlimab combined with tislelizumab or pembrolizumab followed by a placebo. All treatments are given through intravenous infusion. The study monitors overall survival, quality of life, and side effects.

Ociperlimab is an experimental anti-TIGIT antibody that may enhance immune response against cancer. Tislelizumab blocks the PD-1 protein to help the immune system recognize cancer cells. Pembrolizumab also targets PD-1 to boost the immune system’s ability to fight cancer.

Study of BMS-986315 and Nivolumab with Chemotherapy for First-line Treatment in Stage IV or Recurrent Non-Small Cell Lung Cancer Patients

This trial tests BMS-986315 and nivolumab combined with chemotherapy as first-line treatment. Participants must be at least 18 years old with stage IV or recurrent cancer, measurable disease according to RECIST v1.1, and an ECOG Performance Status of 0 or 1. They must have a life expectancy of at least 3 months and this must be their first treatment for advanced disease.

Patients with severe allergic reactions to similar medications, uncontrolled heart conditions, active infections requiring antibiotics, or those pregnant or breastfeeding cannot participate. People with autoimmune diseases or significant liver or kidney disease are also excluded.

The study has two parts. The first assesses safety of the BMS-986315 and nivolumab combination with chemotherapy. The second compares how well this combination works versus nivolumab with chemotherapy alone in reducing tumor size.

BMS-986315 is an experimental medication being tested to help the immune system fight cancer. Nivolumab helps the immune system recognize and attack cancer cells by blocking proteins that prevent immune response. Chemotherapy drugs kill cancer cells or stop them from growing.

Study of CLN-081 tablets in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum chemotherapy

This trial investigates CLN-081 for patients with lung cancer that has a specific genetic change called EGFR Exon 20 insertion mutations. Participants must be at least 18 years old with cancer that has continued growing after platinum-based chemotherapy. They must have measurable tumors, be able to swallow pills, and have acceptable blood test results including adequate kidney and liver function.

Patients with untreated or active brain or spinal cord metastases, previous treatment with EGFR exon 20 insertion mutation-specific inhibitors, or active cardiovascular disease cannot participate. Pregnant or breastfeeding women and those with active infections are also excluded.

Participants take CLN-081 tablets by mouth twice daily with food. The study monitors tumor response using imaging scans and tracks side effects. Doctors also conduct blood tests to measure medication levels and effectiveness.

CLN-081 is an oral medication targeting lung cancers with EGFR exon 20 insertion mutations. It works by blocking specific signals cancer cells use to grow and spread, specifically designed for patients whose cancer was previously treated with platinum-based chemotherapy.

Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

This study tests INCB099280 for patients with advanced or recurrent solid tumors who haven’t received immunotherapy. Participants must be at least 18 years old with measurable disease according to RECIST v1.1 guidelines, an ECOG performance score of 0 or 1, and a life expectancy exceeding 3 months. They must be willing to avoid becoming pregnant or fathering children during the study.

Patients who already received immunotherapy, have medical conditions the study isn’t designed to treat, or fall outside the specified age range cannot participate. Those belonging to vulnerable populations the study cannot safely include are also excluded.

INCB099280 is taken as a film-coated tablet orally at doses of 400 mg, 600 mg, or 800 mg twice daily. The treatment can last up to 24 weeks. Participants are monitored for side effects and changes in their condition throughout the study.

INCB099280 is an investigational medication being studied for its safety, tolerability, and potential effectiveness in treating advanced solid tumors. It works by modulating the immune system to enhance the body’s ability to fight cancer cells.

Study of platinum, pemetrexed, atezolizumab and bevacizumab combination in patients with advanced non-small cell lung cancer who have EGFR, ALK or ROS1 mutations and progressed after targeted therapy

This study focuses on patients with non-squamous lung cancer (stage IIIB/IV) who have specific genetic changes and whose disease progressed after targeted treatments. Participants must be at least 18 years old with measurable disease, ECOG score of 0 or 1, and adequate blood cell counts, liver enzymes, and kidney function. They can have brain metastases if they don’t cause symptoms and don’t require increasing steroid doses.

Patients with untreated brain metastases, previous immunotherapy treatment, active hepatitis B or C infection, autoimmune diseases, or significant heart conditions cannot participate. Pregnant or breastfeeding women and those with other active cancers in the past 5 years are also excluded.

Participants receive a combination of platinum-based chemotherapy, pemetrexed, atezolizumab, and in some cases bevacizumab through intravenous infusion. The study measures how many patients respond to treatment after 4 cycles, tracking disease progression and cancer-related symptoms.

The investigational drugs include carboplatin and cisplatin (platinum-based chemotherapy), pemetrexed (blocking substances needed by cancer cells), atezolizumab (immunotherapy helping the immune system fight cancer), and bevacizumab (blocking new blood vessel growth that feeds tumors).

Summary

The 16 ongoing clinical trials for recurrent non-small cell lung cancer show a concentration of research activity across Europe, with France, Italy, and Spain hosting the largest number of studies. Many trials focus on immunotherapy combinations, particularly using nivolumab, pembrolizumab, and atezolizumab paired with chemotherapy. Several studies target specific genetic mutations, including EGFR, ALK, ROS1, and KRASG12C, reflecting the growing importance of personalized medicine approaches. The trials span multiple European countries, with some studies also including participants from Germany, Poland, Romania, and the Netherlands, demonstrating strong international collaboration in lung cancer research.

#1 Clinical Trials Search in Europe

Non-small cell lung cancer recurrent – Trials in Disease

Ongoing Clinical Trials for Non-Small Cell Lung Cancer Recurrent

Clinical trial locations

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

Study Comparing Ensartinib and Crizotinib for Patients with ALK-Positive Non-Small Cell Lung Cancer

Study of INCB099280 and Adagrasib for Adults with Advanced Solid Tumors with KRASG12C Mutation

Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Study of BMS-986315 and Nivolumab with Chemotherapy for First-line Treatment in Stage IV or Recurrent Non-Small Cell Lung Cancer Patients

Study of CLN-081 tablets in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum chemotherapy

Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

Study of platinum, pemetrexed, atezolizumab and bevacizumab combination in patients with advanced non-small cell lung cancer who have EGFR, ALK or ROS1 mutations and progressed after targeted therapy

Summary

Ongoing Clinical Trials on Non-small cell lung cancer recurrent

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

Study of INCB099280 and Adagrasib for Adults with Advanced Solid Tumors with KRASG12C Mutation

Study on Osimertinib and Savolitinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Previous Osimertinib Treatment

Study on the Safety and Effectiveness of Azacitidine and Pembrolizumab for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Platinum Treatment

Study of CLN-081 tablets in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum chemotherapy

Study of platinum, pemetrexed, atezolizumab and bevacizumab combination in patients with advanced non-small cell lung cancer who have EGFR, ALK or ROS1 mutations and progressed after targeted therapy

Study Comparing Ensartinib and Crizotinib for Patients with ALK-Positive Non-Small Cell Lung Cancer

Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer

Study of BMS-986315 and Nivolumab with Chemotherapy for First-line Treatment in Stage IV or Recurrent Non-Small Cell Lung Cancer Patients

Connected medications:

Non-small cell lung cancer recurrent – Trials in Disease

Ongoing Clinical Trials for Non-Small Cell Lung Cancer Recurrent

Clinical trial locations

Summary

Ongoing Clinical Trials on Non-small cell lung cancer recurrent

More information aboutNon-small cell lung cancer recurrent:

Connected medications:

We use cookies

More information about
Non-small cell lung cancer recurrent: